Long-Term Antidepressant Use May Increase Risk of Sudden Cardiac Death

Why It Matters

The findings raise concerns for clinicians prescribing chronic antidepressant therapy, highlighting a potential cardiovascular safety gap that may influence monitoring guidelines and risk‑benefit assessments.

Key Takeaways

• Study examined >4 million Danish adults, 6,002 sudden cardiac deaths
• 32% of SCD cases involved antidepressant users
• Hazard ratio 1.74 for ≥6 years antidepressant use
• Risk observed for SSRIs and tricyclics after adjustment
• Authors stress findings are associative, not causal

Pulse Analysis

The new analysis published in Heart Rhythm leverages Denmark’s exhaustive death registry to explore a possible link between antidepressant therapy and sudden cardiac death (SCD). Researchers tracked more than four million adults, identifying 6,002 SCD events that were manually verified. By cross‑referencing prescription records, they determined that nearly one‑third of those deaths occurred among individuals who had filled antidepressant prescriptions. The sheer scale of the dataset gives the findings statistical weight, while the rigorous case‑validation reduces misclassification that often plagues pharmaco‑epidemiology studies.

Adjusted analyses revealed a 41 % increase in SCD risk for patients using antidepressants one to five years, rising to a 74 % elevation after six or more years of continuous exposure. The association persisted across major drug subclasses, including selective serotonin reuptake inhibitors and tricyclic agents, even after controlling for comorbidities such as hypertension and diabetes. Notably, the risk gradient diminished among former users, suggesting a time‑dependent component. However, the observational design cannot fully separate medication effects from the underlying severity of depressive illness, leaving residual confounding a plausible alternative explanation.

For prescribers, the study underscores the need for heightened cardiovascular surveillance in patients on long‑term antidepressants, especially those with existing risk factors. It may also prompt regulatory bodies to revisit labeling requirements and encourage the integration of cardiac monitoring into mental‑health treatment protocols. Researchers are calling for prospective trials that can isolate drug‑specific mechanisms, such as QT‑interval prolongation, from the physiological stress of chronic depression. Until causality is established, clinicians should balance psychiatric benefits against potential cardiac hazards on a case‑by‑case basis.